B-intervention	0	11	Palbociclib
O	12	14	in
O	15	22	Hormone
O	22	23	-
O	23	31	Receptor
O	31	32	-
O	32	40	Positive
O	41	49	Advanced
O	50	56	Breast
O	57	63	Cancer
O	63	64	.

O	65	71	Growth
O	72	74	of
O	75	82	hormone
O	82	83	-
O	83	91	receptor
O	91	92	-
O	92	100	positive
O	101	107	breast
O	108	114	cancer
O	115	117	is
O	118	127	dependent
O	128	130	on
O	131	137	cyclin
O	137	138	-
O	138	147	dependent
O	148	155	kinases
O	156	157	4
O	158	161	and
O	162	163	6
O	164	165	(
O	165	169	CDK4
O	170	173	and
O	174	178	CDK6
O	178	179	)
O	179	180	,
O	181	186	which
O	187	194	promote
O	195	206	progression
O	207	211	from
O	212	215	the
O	216	218	G1
O	219	224	phase
O	225	227	to
O	228	231	the
O	232	233	S
O	234	239	phase
O	240	242	of
O	243	246	the
O	247	251	cell
O	252	257	cycle
O	257	258	.

O	259	261	We
O	262	270	assessed
O	271	274	the
O	275	283	efficacy
O	284	286	of
O	287	298	palbociclib
O	299	300	(
O	300	302	an
O	303	312	inhibitor
O	313	315	of
O	316	320	CDK4
O	321	324	and
O	325	329	CDK6
O	329	330	)
O	331	334	and
O	335	346	fulvestrant
O	347	349	in
O	350	358	advanced
O	359	365	breast
O	366	372	cancer
O	372	373	.

O	374	378	This
O	379	384	phase
O	385	386	3
O	387	392	study
O	393	401	involved
B-total-participants	402	405	521
O	406	414	patients
O	415	419	with
O	420	428	advanced
O	429	436	hormone
O	436	437	-
O	437	445	receptor
O	445	446	-
O	446	454	positive
O	454	455	,
O	456	461	human
O	462	471	epidermal
O	472	478	growth
O	479	485	factor
O	486	494	receptor
O	495	496	2
O	496	497	-
O	497	505	negative
O	506	512	breast
O	513	519	cancer
O	520	524	that
O	525	528	had
O	529	537	relapsed
O	538	540	or
O	541	551	progressed
O	552	558	during
O	559	564	prior
O	565	574	endocrine
O	575	582	therapy
O	582	583	.

O	584	586	We
O	587	595	randomly
O	596	604	assigned
O	605	613	patients
O	614	616	in
O	617	618	a
O	619	620	2
O	620	621	:
O	621	622	1
O	623	628	ratio
O	629	631	to
O	632	639	receive
O	640	651	palbociclib
O	652	655	and
O	656	667	fulvestrant
O	668	670	or
B-control	671	678	placebo
I-control	679	682	and
I-control	683	694	fulvestrant
O	694	695	.

O	696	709	Premenopausal
O	710	712	or
O	713	727	perimenopausal
O	728	733	women
O	734	738	also
O	739	747	received
O	748	757	goserelin
O	757	758	.

O	759	762	The
O	763	770	primary
O	771	774	end
O	775	780	point
O	781	784	was
O	785	797	investigator
O	797	798	-
O	798	806	assessed
B-outcome-Measure	807	818	progression
I-outcome-Measure	818	819	-
I-outcome-Measure	819	823	free
I-outcome-Measure	824	832	survival
O	832	833	.

O	834	843	Secondary
O	844	847	end
O	848	854	points
O	855	863	included
B-outcome-Measure	864	871	overall
I-outcome-Measure	872	880	survival
O	880	881	,
B-outcome-Measure	882	891	objective
I-outcome-Measure	892	900	response
O	900	901	,
B-outcome-Measure	902	906	rate
I-outcome-Measure	907	909	of
I-outcome-Measure	910	918	clinical
I-outcome-Measure	919	926	benefit
O	926	927	,
B-outcome-Measure	928	935	patient
I-outcome-Measure	935	936	-
I-outcome-Measure	936	944	reported
I-outcome-Measure	945	953	outcomes
O	953	954	,
O	955	958	and
B-outcome-Measure	959	965	safety
O	965	966	.

O	967	968	A
O	969	979	preplanned
O	980	987	interim
O	988	996	analysis
O	997	1000	was
O	1001	1010	performed
O	1011	1013	by
O	1014	1016	an
O	1017	1028	independent
O	1029	1033	data
O	1034	1037	and
O	1038	1044	safety
O	1045	1055	monitoring
O	1056	1065	committee
O	1066	1071	after
O	1072	1075	195
O	1076	1082	events
O	1083	1085	of
O	1086	1093	disease
O	1094	1105	progression
O	1106	1108	or
O	1109	1114	death
O	1115	1118	had
O	1119	1127	occurred
O	1127	1128	.

O	1129	1132	The
B-outcome	1133	1139	median
I-outcome	1140	1151	progression
I-outcome	1151	1152	-
I-outcome	1152	1156	free
I-outcome	1157	1165	survival
O	1166	1169	was
B-iv-cont-median	1170	1171	9
I-iv-cont-median	1171	1172	.
I-iv-cont-median	1172	1173	2
I-iv-cont-median	1174	1180	months
O	1181	1182	(
O	1182	1184	95
O	1184	1185	%
O	1186	1196	confidence
O	1197	1205	interval
O	1206	1207	[
O	1207	1209	CI
O	1209	1210	]
O	1210	1211	,
O	1212	1213	7
O	1213	1214	.
O	1214	1215	5
O	1216	1218	to
O	1219	1222	not
O	1223	1232	estimable
O	1232	1233	)
O	1234	1238	with
O	1239	1250	palbociclib
O	1250	1251	-
O	1251	1262	fulvestrant
O	1263	1266	and
B-cv-cont-median	1267	1268	3
I-cv-cont-median	1268	1269	.
I-cv-cont-median	1269	1270	8
I-cv-cont-median	1271	1277	months
O	1278	1279	(
O	1279	1281	95
O	1281	1282	%
O	1283	1285	CI
O	1285	1286	,
O	1287	1288	3
O	1288	1289	.
O	1289	1290	5
O	1291	1293	to
O	1294	1295	5
O	1295	1296	.
O	1296	1297	5
O	1297	1298	)
O	1299	1303	with
O	1304	1311	placebo
O	1311	1312	-
O	1312	1323	fulvestrant
O	1324	1325	(
O	1325	1331	hazard
O	1332	1337	ratio
O	1338	1341	for
O	1342	1349	disease
O	1350	1361	progression
O	1362	1364	or
O	1365	1370	death
O	1370	1371	,
O	1372	1373	0
O	1373	1374	.
O	1374	1376	42
O	1376	1377	;
O	1378	1380	95
O	1380	1381	%
O	1382	1384	CI
O	1384	1385	,
O	1386	1387	0
O	1387	1388	.
O	1388	1390	32
O	1391	1393	to
O	1394	1395	0
O	1395	1396	.
O	1396	1398	56
O	1398	1399	;
O	1400	1401	P
O	1401	1402	<
O	1402	1403	0
O	1403	1404	.
O	1404	1407	001
O	1407	1408	)
O	1408	1409	.

O	1410	1413	The
O	1414	1418	most
O	1419	1425	common
B-outcome	1426	1431	grade
I-outcome	1432	1433	3
I-outcome	1434	1436	or
I-outcome	1437	1438	4
I-outcome	1439	1446	adverse
I-outcome	1447	1453	events
O	1454	1456	in
O	1457	1460	the
O	1461	1472	palbociclib
O	1472	1473	-
O	1473	1484	fulvestrant
O	1485	1490	group
O	1491	1495	were
B-outcome	1496	1507	neutropenia
O	1508	1509	(
B-iv-bin-percent	1509	1511	62
I-iv-bin-percent	1511	1512	.
I-iv-bin-percent	1512	1513	0
I-iv-bin-percent	1513	1514	%
O	1514	1515	,
O	1516	1518	vs
O	1518	1519	.
B-cv-bin-percent	1520	1521	0
I-cv-bin-percent	1521	1522	.
I-cv-bin-percent	1522	1523	6
I-cv-bin-percent	1523	1524	%
O	1525	1527	in
O	1528	1531	the
O	1532	1539	placebo
O	1539	1540	-
O	1540	1551	fulvestrant
O	1552	1557	group
O	1557	1558	)
O	1558	1559	,
B-outcome	1560	1570	leukopenia
O	1571	1572	(
B-iv-bin-percent	1572	1574	25
I-iv-bin-percent	1574	1575	.
I-iv-bin-percent	1575	1576	2
I-iv-bin-percent	1576	1577	%
O	1578	1580	vs
O	1580	1581	.
B-cv-bin-percent	1582	1583	0
I-cv-bin-percent	1583	1584	.
I-cv-bin-percent	1584	1585	6
I-cv-bin-percent	1585	1586	%
O	1586	1587	)
O	1587	1588	,
B-outcome	1589	1595	anemia
O	1596	1597	(
B-iv-bin-percent	1597	1598	2
I-iv-bin-percent	1598	1599	.
I-iv-bin-percent	1599	1600	6
I-iv-bin-percent	1600	1601	%
O	1602	1604	vs
O	1604	1605	.
B-cv-bin-percent	1606	1607	1
I-cv-bin-percent	1607	1608	.
I-cv-bin-percent	1608	1609	7
I-cv-bin-percent	1609	1610	%
O	1610	1611	)
O	1611	1612	,
B-outcome	1613	1629	thrombocytopenia
O	1630	1631	(
B-iv-bin-percent	1631	1632	2
I-iv-bin-percent	1632	1633	.
I-iv-bin-percent	1633	1634	3
I-iv-bin-percent	1634	1635	%
O	1636	1638	vs
O	1638	1639	.
B-cv-bin-percent	1640	1641	0
I-cv-bin-percent	1641	1642	%
O	1642	1643	)
O	1643	1644	,
O	1645	1648	and
B-outcome	1649	1656	fatigue
O	1657	1658	(
B-iv-bin-percent	1658	1659	2
I-iv-bin-percent	1659	1660	.
I-iv-bin-percent	1660	1661	0
I-iv-bin-percent	1661	1662	%
O	1663	1665	vs
O	1665	1666	.
B-cv-bin-percent	1667	1668	1
I-cv-bin-percent	1668	1669	.
I-cv-bin-percent	1669	1670	2
I-cv-bin-percent	1670	1671	%
O	1671	1672	)
O	1672	1673	.

B-outcome	1674	1681	Febrile
I-outcome	1682	1693	neutropenia
O	1694	1697	was
O	1698	1706	reported
O	1707	1709	in
B-iv-bin-percent	1710	1711	0
I-iv-bin-percent	1711	1712	.
I-iv-bin-percent	1712	1713	6
I-iv-bin-percent	1713	1714	%
O	1715	1717	of
O	1718	1729	palbociclib
O	1729	1730	-
O	1730	1737	treated
O	1738	1746	patients
O	1747	1750	and
B-cv-bin-percent	1751	1752	0
I-cv-bin-percent	1752	1753	.
I-cv-bin-percent	1753	1754	6
I-cv-bin-percent	1754	1755	%
O	1756	1758	of
O	1759	1766	placebo
O	1766	1767	-
O	1767	1774	treated
O	1775	1783	patients
O	1783	1784	.

O	1785	1788	The
B-outcome	1789	1793	rate
I-outcome	1794	1796	of
I-outcome	1797	1812	discontinuation
I-outcome	1813	1816	due
I-outcome	1817	1819	to
I-outcome	1820	1827	adverse
I-outcome	1828	1834	events
O	1835	1838	was
B-iv-bin-percent	1839	1840	2
I-iv-bin-percent	1840	1841	.
I-iv-bin-percent	1841	1842	6
I-iv-bin-percent	1842	1843	%
O	1844	1848	with
O	1849	1860	palbociclib
O	1861	1864	and
B-cv-bin-percent	1865	1866	1
I-cv-bin-percent	1866	1867	.
I-cv-bin-percent	1867	1868	7
I-cv-bin-percent	1868	1869	%
O	1870	1874	with
O	1875	1882	placebo
O	1882	1883	.

O	1884	1889	Among
O	1890	1898	patients
O	1899	1903	with
O	1904	1911	hormone
O	1911	1912	-
O	1912	1920	receptor
O	1920	1921	-
O	1921	1929	positive
O	1930	1940	metastatic
O	1941	1947	breast
O	1948	1954	cancer
O	1955	1958	who
O	1959	1962	had
O	1963	1974	progression
O	1975	1977	of
O	1978	1985	disease
O	1986	1992	during
O	1993	1998	prior
O	1999	2008	endocrine
O	2009	2016	therapy
O	2016	2017	,
O	2018	2029	palbociclib
O	2030	2038	combined
O	2039	2043	with
O	2044	2055	fulvestrant
O	2056	2064	resulted
O	2065	2067	in
O	2068	2074	longer
O	2075	2086	progression
O	2086	2087	-
O	2087	2091	free
O	2092	2100	survival
O	2101	2105	than
O	2106	2117	fulvestrant
O	2118	2123	alone
O	2123	2124	.

O	2125	2126	(
O	2126	2132	Funded
O	2133	2135	by
O	2136	2142	Pfizer
O	2142	2143	;
O	2144	2151	PALOMA3
O	2152	2166	ClinicalTrials
O	2166	2167	.
O	2168	2171	gov
O	2172	2178	number
O	2178	2179	,
O	2180	2191	NCT01942135
O	2191	2192	.
O	2192	2193	)
O	2193	2194	.
